Striatal neurodegeneration in the presymptomatic phase of X-linked Dystonia-Parkinsonism
Objective: To identify structural brain changes in patients with X-linked dystonia-parkinsonism (XDP) and non-manifesting carriers of the TAF1 SVA retrotransposon insertion (NMC). Background: XDP is…Perillyl alcohol restores mitochondrial dysfunction and abridge NLRP3 inflammasomes activation in in-vitro and in-vivo model of Parkinson’s disease
Objective: Parkinson's disease (PD) affects around 2-3% population of age greater than 65 and is the second most common neurogenerative disorder. The molecular mechanism underpinning…Dopaminergic denervation in de-novo Parkinson’s disease. Does functional somatotopy plays a role?
Objective: To clarify how dopaminergic denervation occurs along the dorsoventral axis of the posterior putamen in the earliest stages of PD. Background: Dopamine loss in…Depression in various forms of parkinsonism and striatal hyperkinesis
Objective: To examine of the degree of depression in various forms of Parkinsonism and striatal hyperkinesis Background: Depression is the basis of affective disorders. Almost…Characterization of striatal dopaminergic neurotransmission in the rat pre-formed fibril models of Parkinson’s disease
Objective: To determine the longitudinal effects of synucleinopathy and synucleinopathy-triggered nigrostriatal degeneration on basal and evoked striatal dopamine (DA) release in the striatum at 4…Blood-Brain Barrier Opening with Focused Ultrasound in Parkinson´s Disease with Cognitive Impairment: A Safety and Feasibility Study
Objective: To evaluate the safety and feasibility of MR guided focused ultrasound (MRgFUS) blood-brain barrier (BBB) opening in the cortex or the striatum in Parkinson´s…Change of extracellular glutamate and GABA level in striatum during deep brain stimulation of the entopeduncular nucleus in rats
Objective: Globus pallidus interna (GPi) is recognized as an effective treatment for advanced Parkinson’s disease. However, the neurochemical basis of its effects remains unknown. The…Phosphodiesterase 10A and cognition in Parkinson’s disease
Objective: We aimed to assess the associations between Phosphodiesterase 10A (PDE10A) expression in the executive striatum and cognitive performance in vivo, using [11C]IMA107 PET and…Imaging biomarker for progression of motor symptoms in advanced Parkinson’s disease
Objective: The aim of the present study is to clarify correlation between motor deficits and dopaminergic neuronal loss in advanced Parkinson’s disease (PD). Background: Series…The Use of Diffusion Weighted Imaging to Detect Structural Biomarkers in Recently-Diagnosed Parkinson’s Disease Patients
Objective: To quantify biomarkers for recently-diagnosed PD patients in the midbrain and their dopaminergic connections to the striatum. Background: The development of improved PD treatments…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 10
- Next Page »